A detailed history of Citigroup Inc transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Citigroup Inc holds 22,097 shares of DMAC stock, worth $98,994. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,097
Holding current value
$98,994
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.8 - $4.49 $61,871 - $99,215
22,097 New
22,097 $92,000
Q2 2022

Aug 10, 2022

SELL
$1.86 - $2.62 $507 - $715
-273 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$2.29 - $3.88 $625 - $1,059
273 New
273 $1,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $118M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.